Advantage of this IPD meta-analysis is that we overcome certain limitations of individual studies, e.g. lack of power, no randomisation to high-dose HDF, and no power for subgroup analyses.

Yet, methodological and clinical heterogeneity is always an issue in meta-analysing studies.

Thanks @hswapnil.bsky.social and @nephroseeker.bsky.social for discussing our paper.

Obviously also curious on the results of H4RT, will add a lot of new information to the puzzle.